临床研究中心

临床试验和研究是寶康醫院临床研究中心实践循证临床研究的关键组成部分。

临床试验为癌症患者测试新的治疗方式，如新的药物、新的治疗组合、新的手术方式或放射治疗，又或者是全新疗法如基因治疗。这些研究和试验的最终目标，就是要找出更多更好的方式来治疗癌症，帮助癌症患者。

临床试验和研究是寶康醫院临床研究中心实践循证临床研究的关键组成部分。

临床试验为癌症患者测试新的疗法，例如新的药物，新的治疗组合，新的途径（手术或放射疗法）或新的疗法（基因疗法）。这些研究的目的是为了找到更好的方法来治疗癌症并帮助癌症患者。

如果在研究中得以证明一项新的治疗是有效的，它将可能成为可以帮助更多患者的新标准疗法。如今，大多数最有效的标准治疗方法都是基于先前的研究成果，例如乳腺癌，结肠癌，直肠癌和儿童期癌症的治疗结果。

参与临床实验的患者可能会从疗程中获益。参与试验者从癌症专家那里得到最新的护理，他们将接受目前处于测试阶段的新疗法或针对他们的癌症而定制的最佳标准疗法。

由于不能保证所测试的新疗法不会带来风险或产生良好的结果，但是如果新疗法被证明比标准疗法有效或更有效，则临床试验的参与者可能是第一个受益的人。

研究对于提高治疗水平非常重要，但寶康醫院的临床研究中心把参与临床试验参与者的权利，安全和福祉作为优先考量事项。除了我们所有的临床研究均已获得马来西亚卫生部医学和研究伦理委员会的核准外，我们也遵守本地和国际良好临床实践（GCP）标准，以维护试验者的道德利益。

迄今为止，我们的肿瘤科团队已参与了不少临床试验，其中包括比较不同化疗方案的疗效；对抑制剂的抵抗；鼻咽癌的表观遗传变化；以及晚期或转移性胃食管癌的治疗方案等。

序	标题	状态
1	MS200095-0031-INSIGHT 2 A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplifies, advanced or metastatic non-small cell lung cancer(NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1^st to 3^rd generation EGFR-tyrosine kinase inhibitor therapy.	进行中(招募病人)
2	ATORG 001 A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study).	进行中(招募病人)
3	MK7902-007 A Phase III, randomized, double-blind trial of Pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007).	进行中(招募病人)
4	CT-P16 3.1 A double-blind, randomized, active-controlled, parallel-Group, Phase 3 study to compare efficacy and safety of CT-P16 and EU-approved Avastin as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.	进行中(招募病人)
5	A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety, and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer	进行中(停止招募病人)
6	MK3475-394 A Phase III Randomized Double-Blind study of pembrolizumab plus best supportive care as second-line therapy in Asian subjects with previously systematically treated advanced hepatocellular carcinoma	进行中(停止招募病人)
7	Keynote-590 A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination of cisplatin and 5-fluorouracil versus placebo in combination with cisplatin and 5-fluorouracil as first-line treatment in subjects with advanced/metastatic esophageal carcinoma	进行中(停止招募病人)
8	Tessa FF01: A Multicentre, Randomised, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine andCarboplatin as first line treatment for Advanced NPC	进行中(停止招募病人)
9	MK3475-042: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)	进行中(停止招募病人)
10	CLEE011A2404 An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocliclib (LEE11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease	进行中(停止招募病人)
11	EMR200095-006 Phase Ib/II Multicentre, Randomized Open Label Trial to Compare (MSC2156119J) Combined Gefitinib Versus Chemotherapy as Second Line Treatment in Subject with MET (+), Locally Advanced / Metastatic Non-Small Lung Cancer (NSCLC) Harbouring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor	进行中(停止招募病人)
12	CT10-01 Malaysian Cell Therapy Patient Registry: A Patient Registry (clinical database) to Evaluate the Health Outcomes of Patients who had received Cell Therapy In Malaysia	即将到来(CTA / 预算审查)
13	Studies On Epigenetic Changes In Nasopharyngeal Cancer	完成
14	Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care	完成
15	Healthcare Performance Measurement And Reporting For Breast Cancer Services In Malaysia	完成(View abstract) (View paper)
16	A Randomized, Phase II, Placebo Controlled Study Of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma	完成
17	A Randomized, 3 Arm, Multicentre, Phase III Study To Evaluate	完成
18	A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors.	完成
19	An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC)	完成

除了肿瘤学临床试验，来自其他卓越中心的顾问也通过发表研究论文为临床专业做出了重大贡献。以下是我们的顾问发表的研究成果（摘要、研究论文、海报等）：

No	标题	顾问医生	刊物类型
1	Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical Photographs	Dr Ong Chin Tuan (Consultant Ophthalmologist)	Poster